SI-BONE, Inc.NASDAQ: SIBN

SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026

· Issued by SI-BONE, Inc. via GlobeNewswire

Summary by 6ix AI

SI-BONE, Inc., which develops procedures and devices for treating weakened bone, will report its financial results for the third quarter of 2026 after market close on Monday, November 2, 2026.

Key details

  • Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time, with live audio webcast on the Investors section of the company's website.
  • The webcast will be archived and available for replay for at least 90 days after the event.

6ix AI wrote this summary from the release below and checked it against the release.

SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the third quarter of 2026 after market close on Monday, November 2, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/qa2u8o97/. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (Nasdaq: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing over 150,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 190 peer reviewed publications.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved

Investor Contact: Saqib Iqbal, investors@si-bone.com


View original source (GlobeNewswire)SI-BONE, Inc. on 6ix

Story so far

Earlier from SI-BONE

All SI-BONE news releases